HolderBook

MOONLAKE IMMUNOTHERAPEUTICS (MLTX)

Institutional ownership reported to the SEC as of Q3 2026, across 19 quarters.

3
Reporting holders
$2.6M
Reported value
0.0%
Calls
0.0%
Puts
-171
Holder change

Calls and puts are the parts of reported value carried in derivative lines rather than shares, and they point in opposite directions: a manager holding calls is positioned for the security, one holding puts against it - or hedging shares they already own, which is why index funds carry so many. Most sites add the two together and report one figure, which averages away the only interesting part.

Holders

Download these holders as CSV

FilerValueShares Their book Held Change
CONGRESS ASSET MANAGEMENT CO$2.6M223,8830.02%9q+24.1%+$508.2K
Farther Finance Advisors, LLC$2.2K1910.00%5q-78.4%-$8.1K
GAMMA Investing LLC$164140.00%2qHELD

Five percent filings

Anyone crossing 5% of a company must say so within days - far sooner than the next quarterly holdings report. A 13D declares an intent to influence the company; a 13G is the passive version. See all activist filings →

FiledFormFiler % of class
2026-08-1413G/ADeep Track Capital, LPwith 2 co-filers9.7%
2026-08-1413G/ACormorant Asset Management, LPwith 1 co-filers4.3%
2026-08-1413GT. Rowe Price Investment Management, Inc.5.3%

What the insiders did

Open market purchases and sales reported on Form 4 in the last 180 days. Grants, option exercises and shares surrendered to cover tax are left out: they are compensation rather than a decision to buy or sell. Where a broker filled one order in tranches the lines are summed, because it was one decision.

Officers and directors

DateInsiderRoleSideSharesValue
2026-07-10Santos da Silva JorgeChief Executive OfficerSold68,289$1.4M
2026-07-21Reich KristianChief Scientific OfficerSold50,000$1.0M
2026-06-17Reich KristianChief Scientific OfficerSold50,000$971.5K
2026-07-01Santos da Silva JorgeChief Executive OfficerSold47,775$956.9K
2026-06-15Reich KristianChief Scientific OfficerSold50,000$944.5K
2026-06-16Reich KristianChief Scientific OfficerSold50,000$935.0K
2026-07-20Reich KristianChief Scientific OfficerSold43,700$877.9K
2026-06-22Bodenstedt MatthiasChief Financial OfficerSold39,120$862.2K
2026-07-09Santos da Silva JorgeChief Executive OfficerSold33,936$679.1K
2026-07-15Reich KristianChief Scientific OfficerSold16,105$322.3K
2026-06-17Bodenstedt MatthiasChief Financial OfficerSold15,082$296.8K
2026-05-11Bodenstedt MatthiasChief Financial OfficerSold13,653$273.3K

Quarter by quarter

Coverage begins with the quarter ending 2018-12-31. Earlier filings exist only as occasional late amendments, too sparse to describe a market, so they are not shown.

QuarterHoldersValue SharesNewAdded TrimmedOptions
Q3 20263$2.6M224,0880110.0%
Q2 2026174$1.5B75,791,8974173423.5%
Q1 2026148$1.2B63,464,9013849423.5%
Q4 2025131$797.2M56,603,9174255226.4%
Q3 2025147$317.1M37,634,62453344115.0%
Q2 2025139$2.8B58,610,2432534532.7%
Q1 2025140$2.4B60,115,9373428391.3%
Q4 2024120$3.4B63,251,0311945330.6%
Q3 2024113$3.1B62,107,0961947240.4%
Q2 2024111$2.7B61,531,1172035360.5%
Q1 2024120$3.1B59,898,8421942381.7%
Q4 2023131$3.6B58,764,7783948322.4%
Q3 2023121$3.3B56,499,7645531252.0%
Q2 202382$2.9B56,252,219462580.0%
Q1 202343$853.3M39,894,581211160.0%
Q4 202233$396.4M37,748,85612660.0%
Q3 202224$291.4M36,855,8475460.0%
Q2 202222$190.1M36,470,00822000.0%
Q1 20221$7.3M653,8721000.0%